论文信息 - Treatment-free remission (TFR) following frontline (1L) nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): 192-week data from the ENESTfreedom study. - 字舞流文

Treatment-free remission (TFR) following frontline (1L) nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): 192-week data from the ENESTfreedom study.

J. Radich | S. Acharyya | F. Giles | G. Saglio | A. Hochhaus | T. Masszi | N. Gattermann | P. Aimone | B. Martino | E. Conneally | A. Hellmann | S. Saussele | D. Ross | J. Stentoft | M. T. G. Casares | V. Gutiérrez | Manu Sondhi | Phillipp D. Le Coutre